Annual Retained Earnings
-$528.38 M
-$132.49 M-33.47%
December 31, 2023
Summary
- As of February 26, 2025, CCCC annual retained earnings is -$528.38 million, with the most recent change of -$132.49 million (-33.47%) on December 31, 2023.
- During the last 3 years, CCCC annual retained earnings has fallen by -$344.56 million (-187.44%).
- CCCC annual retained earnings is now -533.64% below its all-time high of -$83.39 million, reached on December 31, 2018.
Performance
CCCC Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Retained Earnings
-$599.13 M
-$24.67 M-4.29%
September 30, 2024
Summary
- As of February 26, 2025, CCCC quarterly retained earnings is -$599.13 million, with the most recent change of -$24.67 million (-4.29%) on September 30, 2024.
- Over the past year, CCCC quarterly retained earnings has dropped by -$105.50 million (-21.37%).
- CCCC quarterly retained earnings is now -409.95% below its all-time high of -$117.49 million, reached on December 31, 2019.
Performance
CCCC Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Retained Earnings Formula
Retained Earnings = Retained Earnings (start of the period) + Net Income − Dividends Paid
CCCC Retained Earnings Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.5% | -21.4% |
| 3 y3 years | -187.4% | -21.4% |
| 5 y5 years | -533.6% | -21.4% |
CCCC Retained Earnings Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -97.4% | at low | -123.8% | at low |
| 5 y | 5-year | -349.7% | at low | -409.9% | at low |
| alltime | all time | -533.6% | at low | -409.9% | at low |
C4 Therapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -$599.13 M(+4.3%) |
| Jun 2024 | - | -$574.46 M(+3.2%) |
| Mar 2024 | - | -$556.74 M(+5.4%) |
| Dec 2023 | -$528.38 M(+33.5%) | -$528.38 M(+7.0%) |
| Sep 2023 | - | -$493.63 M(+5.8%) |
| Jun 2023 | - | -$466.59 M(+8.3%) |
| Mar 2023 | - | -$430.67 M(+8.8%) |
| Dec 2022 | -$395.89 M | -$395.89 M(+10.4%) |
| Sep 2022 | - | -$358.70 M(+9.8%) |
| Jun 2022 | - | -$326.75 M(+9.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | -$299.33 M(+11.8%) |
| Dec 2021 | -$267.71 M(+45.6%) | -$267.71 M(+6.2%) |
| Sep 2021 | - | -$252.06 M(+10.9%) |
| Jun 2021 | - | -$227.37 M(+11.0%) |
| Mar 2021 | - | -$204.79 M(+11.4%) |
| Dec 2020 | -$183.82 M(+56.5%) | -$183.82 M(+13.5%) |
| Sep 2020 | - | -$162.03 M(+15.6%) |
| Jun 2020 | - | -$140.19 M(+19.3%) |
| Dec 2019 | -$117.49 M(+40.9%) | -$117.49 M |
| Dec 2018 | -$83.39 M | - |
FAQ
- What is C4 Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for C4 Therapeutics?
- What is C4 Therapeutics annual retained earnings year-on-year change?
- What is C4 Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for C4 Therapeutics?
- What is C4 Therapeutics quarterly retained earnings year-on-year change?
What is C4 Therapeutics annual retained earnings?
The current annual retained earnings of CCCC is -$528.38 M
What is the all time high annual retained earnings for C4 Therapeutics?
C4 Therapeutics all-time high annual retained earnings is -$83.39 M
What is C4 Therapeutics annual retained earnings year-on-year change?
Over the past year, CCCC annual retained earnings has changed by -$132.49 M (-33.47%)
What is C4 Therapeutics quarterly retained earnings?
The current quarterly retained earnings of CCCC is -$599.13 M
What is the all time high quarterly retained earnings for C4 Therapeutics?
C4 Therapeutics all-time high quarterly retained earnings is -$117.49 M
What is C4 Therapeutics quarterly retained earnings year-on-year change?
Over the past year, CCCC quarterly retained earnings has changed by -$105.50 M (-21.37%)